DUBLIN, Ireland and TREVOSE, Pa. – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that post hoc analyses from a one year open-label study evaluating daily use of KEVEYIS® (dichlorphenamide) for the treatment...
Latest News
DUBLIN, Ireland and TREVOSE, Pa. – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it submitted a New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the treatment of endogenous Cushing’s syndrome to...
DUBLIN, Ireland and TREVOSE, Pa. – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application...
New York, NY – Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute. The antimalarial molecule, TDI-8304, is one of a new class...
PHILADELPHIA – How molecules of the oldest branch of the human immune system have interconnected has remained a mystery. Now, two new structures, both involving a central component of an enzyme important to the complement system of the immune response, reveal how this system fights invading microbes while avoiding problems...
Munich, Germany – Many important medicines, such as antibiotics and anticancer drugs, are derived from natural products from Bacteria. The enzyme complexes that produce these active ingredients have a modular design that makes them ideal tools for synthetic biology. By exploring protein evolution, a team led by Helge Bode from...
Ridgefield, Conn. – Boehringer Ingelheim today announced results from an analysis of the SENSCIS®-ON trial. SENSCIS-ON is an open-label extension trial of the Phase III SENSCIS® study to assess the long-term tolerability and safety of Ofev® (nintedanib) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study also evaluated...
London, UK – New findings reveal that the body undergoes significant, systematic changes across multiple organs during prolonged periods of fasting. The results demonstrate evidence of health benefits beyond weight loss, but also show that any potentially health-altering changes appear to occur only after three days without food. The study,...
Charlottesville, Virginia – About one-third of autistic people are unable to communicate using speech, and most are never provided an effective alternative. However, a new study from scientists at the University of Virginia suggests that many of these individuals are literate, raising the possibility that they could learn to express...
HOUSTON, TX ― Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings, published today in Nature, open the door for development...